Abstract:Abstract BACKGROUND: Our previous whole-genome sequencing in esophageal squamous-cell carcinoma (ESCC) has identified 23 focal regions with recurrent gain of copy number that contain 1591 genes. Further integrative analysis of copy number alterations with mRNA expression levels showed 141 copy-number amplified genes that had higher mRNA levels, suggesting an important role of these genes in ESCC. This study was to investigate the functional roles of these genes and their potential as biomarkers and therapeutic targets for ESCC. METHODS: An siRNA library was used to knock down all these 141 genes in ESCC cells and change of the malignant phenotype of these cancer cells was examined by using a high-throughput imaging method and in vitro proliferation and colony formation assays. The acting mechanism of the interest genes on malignant phenotypes of cells was explored using biochemical and molecular biological assays. We also examined the effect of the amplified genes on sensitivity of cancer cells to anticancer agents in vitro and in vivo in mice. RESULTS: We found that, among the 141 examined genes, TIGAR was the top one influencing ESCC cell proliferation in vitro and in vivo in xenografts. We confirmed that TIGAR can inhibit glycolysis and divert the carbon flux into the PPP to produce ribose-5-phosphate (R5P) for nuclear synthesis in cells. Overexpression of TIGAR may activate AMPKα that regulated mRNA translation and glutamine-dependent mitochondrial metabolism to maintain energy balance in cells with a reduced glycolysis ability, which was responsible for energy production under normal conditions. We found that ESCC cells overexpressing TIGAR had an addiction to glutamine metabolism and were sensitive to glutaminase inhibitors. Glutamine restriction or glutaminase inhibitors had a synergistic effect with chemotherapy drugs, such as DDP and 5-Fu, on killing of ESCC cells, suggesting that glutaminase inhibitors may be used as adjuvant agents for treatment of ESCC with TIGAR amplification. CONCLUSION: These results suggest that amplification or overexpression of TIGAR may prevent ESCC cells from killing by anticancer drugs and thus may represent a therapeutic target for ESCC. Citation Format: Jiahui Chu, Mingming Shao, Jiang Chang, Qionghua Cui, Linna Peng, Yingying Luo, Wen Tan, Chen Wu, Dongxin Lin. TIGAR amplification promotes glutamine addition in the progression of esophageal squamous cell carcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr LB-246.

TP53-inducible Glycolysis and Apoptosis Regulator (TIGAR) Metabolically Reprograms Carcinoma and Stromal Cells in Breast Cancer

TIGAR promotes malignant proliferation of NSCLC by modulating deoxynucleotide anabolism via a YBX1-RRM2B axis

TP53 Induced Glycolysis and Apoptosis Regulator and Monocarboxylate Transporter 4 drive metabolic reprogramming with c-MYC and NFkB activation in breast cancer

TP53-Induced Glycolysis and Apoptosis Regulator (TIGAR) Is Upregulated in Lymphocytes Stimulated with Concanavalin A

The Diverse Role of TIGAR in Cellular Homeostasis and Cancer

Knockdown of the TP53-Induced Glycolysis and Apoptosis Regulator (TIGAR) Sensitizes Glioma Cells to Hypoxia, Irradiation and Temozolomide

JMJD5 Inhibits Lung Cancer Progression by Regulating Glucose Metabolism Through the P53/tigar Pathway

Structure, regulation, and biological functions of TIGAR and its role in diseases

Metabolic Remodeling by TIGAR Overexpression is a Therapeutic Target in Esophageal Squamous-Cell Carcinoma

TIGAR Enhanced Free Ca2+ Concentration in Hepatocellular Carcinoma Cells to Accelerate the Sustained Proliferation and Drug Resistance

The Impact of TP53-Induced Glycolysis and Apoptosis Regulator on Prognosis in Hepatocellular Carcinoma: Association with Tumor Microenvironment and Ferroptosis

TIGAR Alleviates Ischemia/reperfusion-Induced Autophagy and Ischemic Brain Injury.

Identification of the TP53-induced glycolysis and apoptosis regulator in various stages of colorectal cancer patients

TIGAR is correlated with maximal standardized uptake value on FDG-PET and survival in non-small cell lung cancer.

Knockdown of TIGAR by RNA Interference Induces Apoptosis and Autophagy in HepG2 Hepatocellular Carcinoma Cells.

TIGAR Regulates DNA Damage and Repair Through Pentosephosphate Pathway and Cdk5-ATM Pathway

CD155T/TIGIT Signaling Regulates CD8(+) T-cell Metabolism and Promotes Tumor Progression in Human Gastric Cancer

Immune landscape of hepatocellular carcinoma: The central role of TP53-inducible glycolysis and apoptosis regulator

Abstract LB-246: TIGAR Amplification Promotes Glutamine Addition in the Progression of Esophageal Squamous Cell Carcinoma

TIGAR drives colorectal cancer ferroptosis resistance through ROS/AMPK/SCD1 pathway

TP 53 induced glycolysis and apoptosis regulator knockdown radiosensitizes glioma cells through oxidative stress-induced excessive autophagy